1Rodan GA.Mechaniam of action of bisphosphonates[J].Annu Rev Pharmacol Toxicol,1998,38:375～388. 被引量：1
2Fogelman I,Ribot C,Smith R,et al.Risedronate reverses bone loss in postmenopausal women with low bone mass:results from a multinational,doubled-blind,placebo-controlled trial[J].J clin Endrocrinol Metab,2000,85:1895～1900. 被引量：1
3Mcclung M,Clemmesen B,Daifotis A,et al.Alendronate prevents postmenopausal bone loss in women without osteoporosis[J].Ann intern Med,1998,128:253～261. 被引量：1
5Reid D,Hughes R,Laan RF,et al.Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women:a randomized trial[J].J Bone Miner Res,2000,15:1006～1013. 被引量：1
6Reasner CA,Stone MD,Hosking DJ,et al.Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate[J].J Clin Endocrinol Metab,1993,77:1067～1071. 被引量：1
7Lindsay R,Cosman F,Bobo RA,et al.Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis:a randomized,controlled clinical trial[J].J Clin Endocrinol Metab,1999,84:3076～3081. 被引量：1
8Bone HG,Greenspan SL,McKeever C,et al.Alendronate and estrogen effects in postmenopausal women with low bone mineral density[J].J Clin Endocrinol Metab,2000,85:720～726. 被引量：1
9Mitchell DY,Heise MA,Pallone KA,et al.The effect of dosing regimen on the pharmacokinetics of risedronate[J].Br J Clin Pharmacol,1999,48:536～542. 被引量：1
